{"DataElement":{"publicId":"7374760","version":"1","preferredName":"Kaposi Sarcoma Lesion Additional Information Specify","preferredDefinition":"Text description of additional information related to the Kaposi sarcoma lesion.","longName":"TUCHANGE_SPEC","context":"AMC","contextVersion":"1","DataElementConcept":{"publicId":"7374757","version":"1","preferredName":"Kaposi Sarcoma Lesion Additional Information","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS)._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._Added; extra; further._Knowledge derived from study, experience, or instruction that has been gathered or received by communication.","longName":"7372488v1.0:7374755v1.0","context":"AMC","contextVersion":"1","ObjectClass":{"publicId":"7372488","version":"1","preferredName":"Kaposi Sarcoma Lesion","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","longName":"C9087:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB86C29E-8915-286B-E053-4EBD850A1C5A","latestVersionIndicator":"Yes","beginDate":"2020-07-28","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-07-28","modifiedBy":"ONEDATA","dateModified":"2020-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7374755","version":"1","preferredName":"Additional Information","preferredDefinition":"Added; extra; further.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication.","longName":"C25406:C48191","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Information","conceptCode":"C48191","definition":"Knowledge derived from study, experience, or instruction that has been gathered or received by communication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAED872-669E-73AF-E053-4EBD850A543F","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-07-30","modifiedBy":"ONEDATA","dateModified":"2020-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAED872-66AF-73AF-E053-4EBD850A543F","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-07-30","modifiedBy":"COLLIED","dateModified":"2020-08-27","changeDescription":"Curated for AMC 107 protocol DC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7374759","version":"1","preferredName":"Additional Information Specify","preferredDefinition":"Added; extra; further._Knowledge derived from study, experience, or instruction that has been gathered or received by communication._Be specific about something; define clearly.","longName":"7374759v1.0","context":"AMC","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7374758","version":"1","preferredName":"Additional Information Specify","preferredDefinition":"Added; extra; further.:Knowledge derived from study, experience, or instruction that has been gathered or received by communication.:Be specific about something; define clearly.","longName":"C25406:C48191:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Information","conceptCode":"C48191","definition":"Knowledge derived from study, experience, or instruction that has been gathered or received by communication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAA8214-81F9-5169-E053-4EBD850AB62B","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-07-30","modifiedBy":"ONEDATA","dateModified":"2020-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABAA8214-820A-5169-E053-4EBD850AB62B","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-07-30","modifiedBy":"COLLIED","dateModified":"2020-08-25","changeDescription":"Curated for AMC 107 protocol DC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"7283431","version":"1","longName":"CRF CDEs","context":"AMC","ClassificationSchemeItems":[{"publicId":"7312662","version":"1","longName":"KS","context":"AMC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please provide any additional","type":"Preferred Question Text","description":"Please provide any additional information on lesions that fused, broke apart, or central clearing","url":null,"context":"AMC"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABADD26C-7746-5F24-E053-4EBD850A9260","latestVersionIndicator":"Yes","beginDate":"2020-07-30","endDate":null,"createdBy":"COLLIED","dateCreated":"2020-07-30","modifiedBy":"COLLIED","dateModified":"2020-08-28","changeDescription":"Curated for AMC 107 protocol DC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}